What biomarker tests are recommended for Colorectal Cancer

Biomarker Testing for Colorectal Cancer

Based on current clinical guidelines, here's what you need to know about the biomarker tests recommended for colorectal cancer patients:

Universal Testing (Recommended for All Patients)

Mismatch Repair (MMR) or Microsatellite Instability (MSI) Testing

According to NCCN Guidelines, universal MMR or MSI testing is recommended for all newly diagnosed colorectal cancer patients. Here's why this matters:

• What it detects: These tests identify whether your tumor has defects in DNA repair mechanisms
• How it's done: Either immunohistochemistry (IHC) staining to check for MMR protein expression, or molecular testing for MSI (changes in repetitive DNA patterns)
• Why it matters:
  • Identifies patients who may have Lynch syndrome (a hereditary cancer condition)
  • Guides treatment decisions, especially for stage II disease
  • Determines eligibility for immunotherapy in advanced disease
  • Stage II patients with MSI-high (MSI-H) tumors may have better prognosis and may NOT need chemotherapy

---

Testing for Metastatic (Advanced) Colorectal Cancer

If your cancer has spread, NCCN Guidelines recommend testing for:

RAS and BRAF Mutations

What these are: Genetic changes in tumor cells that affect how the cancer grows

Why testing matters:

• KRAS/NRAS mutations: If present, you cannot receive certain targeted drugs (cetuximab or panitumumab), which are monoclonal antibodies (special proteins that target cancer cells)
• BRAF V600E mutations: Affects response to targeted therapies; typically requires combination treatment approaches

Testing method: Next-generation sequencing (NGS) is preferred, performed on tumor tissue or metastatic sites

---

HER2 Testing

What it detects: Whether your tumor has extra copies of the HER2 gene (amplification)

Testing methods:

• Immunohistochemistry (IHC) - staining tumor tissue
• Fluorescence in situ hybridization (FISH) - specialized DNA testing
• Next-generation sequencing (NGS)

Why it matters: HER2-positive tumors can be treated with targeted therapies like trastuzumab (Herceptin) combined with other HER2-blocking drugs, but only if your tumor is also wild-type (normal) for RAS and BRAF

---

NTRK Fusion Testing

What it detects: A rare genetic rearrangement (approximately 0.35% of colorectal cancers)

Important note: NTRK fusions are extremely rare in colorectal cancer and are more commonly found in tumors with MSI-H status

Testing methods: RNA-based next-generation sequencing is considered optimal for accurate detection

Why it matters: If present, NTRK inhibitors (targeted drugs) can be effective

---

Additional Emerging Biomarkers

POLE/POLD1 Mutations

These are mutations in DNA polymerase genes that create a "hypermutated" tumor (very high mutation burden). According to NCCN Guidelines, these tumors may respond well to immunotherapy, similar to MSI-H tumors.

---

Prognostic Tests (Help Predict Outcomes)

For stage II and III colon cancer, your doctor may consider:

• Circulating Tumor DNA (ctDNA): Blood test detecting cancer DNA after surgery. According to NCCN Guidelines, patients with detectable ctDNA after surgery have significantly higher recurrence risk and may benefit from adjuvant chemotherapy
• Multigene assays (like Oncotype DX, ColoPrint): Analyze gene expression patterns to predict recurrence risk

---

Screening Tests (Early Detection)

If you're at risk for colorectal cancer, newer blood and stool tests are now available:

FDA-Approved Blood Tests:

• Shield (Guardant Health): Blood test detecting cancer DNA methylation patterns; FDA-approved July 2024
• Cologuard Plus: Stool-based DNA test; FDA-approved October 2024

Stool-Based Tests:

• ColoSense: RNA-based stool test; FDA-approved May 2024

---

Key Questions to Ask Your Healthcare Team

1. "Which biomarker tests have been performed on my tumor, and what were the results?"
2. "Do I have MSI-H or dMMR status, and what does this mean for my treatment options?"
3. "What are my RAS, BRAF, and HER2 status, and how do these affect my treatment choices?"
4. "Am I eligible for immunotherapy based on my biomarker results?"
5. "Should I have ctDNA testing after surgery to guide my follow-up care?"
6. "Do I need genetic counseling for Lynch syndrome based on my test results?"

---

Important Clinical Context

According to NCCN Guidelines, testing should be performed only in CLIA-certified laboratories (Clinical Laboratory Improvement Amendments). The specific testing method matters less than ensuring accurate, reliable results from qualified labs.

Note: Repeat molecular testing after standard chemotherapy is generally not recommended, as significant changes are rarely observed. However, repeat testing may be considered after targeted therapies to guide future treatment decisions.

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.